No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 299 | 320 | 390 | 395 | 343 | 475 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | -103 | -165 | -185 | -164 | -261 | -201 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Applied BioCode Corporation (6598.TW)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.